STXS250117P2500
- 0.00
- 0.000.00%
Stereotaxis Newsroom
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
Stereotaxis and MicroPort EP Secure NMPA Approval for Magbot Ablation Catheter in China
Stereotaxis' GenesisX Robotic System to Be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference
Strategic Partnerships and Regulatory Advancements Propel Stereotaxis to Buy Rating
Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)
Stereotaxis Genesis Robotic System Secures Regulatory Approval In China, Marking Key Milestone In Partnership With MicroPort EP For Commercial Launch Of Advanced Robotic And Electrophysiology Solutions
Express News | Stereotaxis Inc: Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
Hospital in Portugal Adopts Stereotaxis Surgical Robot
Stereotaxis Announces That Physicians At The Hospital Da Luz In Lisbon, Portugal Have Successfully Treated The First Patients Using The Advanced Genesis Robotic Magnetic Navigation System
Stereotaxis | 10-Q: Q3 2024 Earnings Report
Piper Sandler Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $4
Stereotaxis | 8-K: Stereotaxis Reports 2024 Third Quarter Financial Results
Piper Sandler Releases a Buy Rating on Stereotaxis (STXS)
Stereotaxis Reports Strong Q3 Growth in Robotics
TD Cowen Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $5
Bullish Outlook on Stereotaxis: Strong Revenue Growth and Promising Pipeline
Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript Summary